Active agent transport systems
    7.
    发明授权
    Active agent transport systems 失效
    活性剂运输系统

    公开(公告)号:US06245359B1

    公开(公告)日:2001-06-12

    申请号:US08941616

    申请日:1997-09-30

    IPC分类号: A61K916

    摘要: Methods for transporting a biologically active agent across a cellular membrane or a lipid bilayer. A first method includes the steps of: (a) providing a biologically active agent which can exist in a native conformational state, a denatured conformational state, and an intermediate conformational state which is reversible to the native state and which is conformationally between the native and denatured states; (b) exposing the biologically active agent to a complexing perturbant to reversibly transform the biologically active agent to the intermediate state and to form a transportable supramolecular complex; and (c) exposing the membrane or bilayer to the supramolecular complex, to transport the biologically active agent across the membrane or bilayer. The perturbant has a molecular weight between about 150 and about 600 daltons, and contains at least one hydrophilic moiety and at least one hydrophobic moiety. The supramolecular complex comprises the perturbant non-covalently bound or complexed with the biologically active agent. In the present invention, the biologically active agent does not form a microsphere after interacting with the perturbant. A method for preparing an orally administrable biologically active agent comprising steps (a) and (b) above is also provided as are oral delivery compositions. Additionally, mimetics and methods for preparing mimetics are contemplated.

    摘要翻译: 运输生物活性剂穿过细胞膜或脂质双层的方法。 第一种方法包括以下步骤:(a)提供可以以天然构象状态,变性构象状态和中和构象状态存在的生物活性剂,其可天然状态是可逆的,并且在天然和/或 变性状态;(b)将生物活性剂暴露于络合扰动剂以将生物活性剂可逆地转化为中间状态并形成可运输的超分子复合物; 和(c)将膜或双层暴露于超分子复合物,以将生物活性剂转运穿过膜或双层。 扰动剂具有约150至约600道尔顿之间的分子量,并且含有至少一个亲水部分和至少一个疏水部分。 超分子复合物包括与生物活性剂非共价结合或络合的扰动剂。 在本发明中,生物活性剂在与扰动剂相互作用后不形成微球体。 还提供了包含上述步骤(a)和(b)的可口服给药的生物活性剂的方法,口服递送组合物也是如此。另外,可以设想模拟物和制备模拟物的方法。

    Intraoral dosage forms of glucagon
    10.
    发明授权
    Intraoral dosage forms of glucagon 有权
    胰高血糖素的口服剂型

    公开(公告)号:US08975227B2

    公开(公告)日:2015-03-10

    申请号:US11994032

    申请日:2006-07-17

    IPC分类号: A61K38/26 C07K14/605

    CPC分类号: A61K38/26 C07K14/605

    摘要: The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and glucagon. Preferably, the composition includes a therapeutically effective amount of glucagon and the delivery agent compound. The composition of the present invention facilitates the delivery of glucagon and increases its bioavailability compared to administration without the delivery agent compound.

    摘要翻译: 本发明提供包含至少一种递送剂化合物和胰高血糖素的组合物(例如,药物组合物)。 优选地,组合物包含治疗有效量的胰高血糖素和递送剂化合物。 本发明的组合物有助于胰高血糖素的递送,并且与不含递送剂化合物的给药相比,其生物利​​用度增加。